Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. BeneChill files for $14m IPO
The red-hot IPO market for medical device companies shows no signs of abating as the year comes to a close, with BeneChill yesterday tossing its hat in the ring for a nearly $14 million flotation.
San Diego-based BeneChill developed a “therapeutic hypothermia” device called the RhinoChill that’s designed to prevent brain damage in cardiac arrest patients. The system uses a catheter to deliver a coolant to the nasal cavity to reduce patients’ temperature. Read more
2. Study: Medtronic’s In.Pact Admiral balloon beats standard angioplasty
Medtronic said a new study found that its drug-eluting balloon performed better than a standard angioplasty balloon in the treatment of symptomatic peripheral artery disease of the upper leg.
The Medtronic-sponsored In.Pact SFA study compared the outcomes of 331 PAD patients in Europe and the U.S. whose narrowed leg arteries were treated either with standard percutaneous transluminal angioplasty or Medtronic’s In.Pact Admiral balloon. Read more
1. Infraredx files for $55m IPO
Infraredx yesterday registered for an initial public offering with the Securities & Exchange Commission, estimating the flotation’s worth at $55 million.
Burlington, Mass.-based Infraredx makes an imaging system that combines intravascular ultrasound and near-infrared spectroscopy to provide images of the interior of coronary blood vessels. Read more